TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Public ClinicalTrials.gov record NCT03032484. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
Study identification
- NCT ID
- NCT03032484
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 17, 2017
- Primary completion
- Apr 3, 2020
- Completion
- Apr 4, 2021
- Last update posted
- Jun 14, 2023
2017 – 2021
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Astrocytoma trials
Other public records listing Astrocytoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT06344130: Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma Recruiting
- NCT03911388: HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Recruiting
- NCT03975829: Pediatric Long-Term Follow-up and Rollover Study Recruiting
- NCT07560865: First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma Recruiting
- NCT06108206: Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma Active, not recruiting
- NCT05484622: Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03032484, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2023 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03032484 live on ClinicalTrials.gov.